Sonny Hsiao, Ph. D.

Member of the Board of Directors、Founder and CEO/ Acepodia, Inc.

• Over 14 years of R&D experience across biotech and academia in the areas of oncology, cell therapies, and immuno-oncology. Served for over several years in leadership roles including chief scientist and CEO. Co-founder of Acepodia, Inc.

• Track record in the discovery of cell therapy products and translation from pre-clinical candidates to FDA-approval phase, including bringing one of my own Berkeley research cell therapy drug candidate to get IND approval and to get into clinical trials in the US.

• Strong experience in advancing innovative and emerging technologies, such as NK cell therapy, gamma delta T

cell therapy, antibody-cell conjugates, adoptive/CAR cell therapies (including donor-derived & cell line approaches).

• Leadership with expertise in building and leading teams across the entire spectrum of drug development, from initial discovery to IND and patent filing, safety, PK/PD, CMC, regulatory, and early-phase clinical trials. Experience in working in a fast-pace environment, including chairing high-level company committees responsible for making go or no-go decisions. Leading scientist with numerous publications and worldwide patent applications and issued patents

• Co-Founder and Chief Executive Officer at Acepodia, Inc. Awarded Dr. Y-T Lee Prize, which named after Nobel Laureate Dr. Lee, for the research achievement in Chemistry. Extensive research experiences in immune cell therapies, which lead to the discovery of ACC (Antibody-Cell Conjugation) technology, and to the invention of the novel cellular immunotherapy, ACE (Antibody-Cell Conjugation Effectors). BS in Chemistry from National Taiwan University, and PhD in Chemistry and Molecular Cell Biology from the University of California, Berkeley.